Ketamine for Obsessive-Compulsive Disorder
(MKET Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how ketamine quickly improves symptoms in people with Obsessive-Compulsive Disorder (OCD). Ketamine works by blocking a specific brain receptor, which helps reduce repetitive thoughts and behaviors. Recent research demonstrated that ketamine rapidly reduces OCD symptoms. The study focuses on how this process happens at different levels in the brain.
Will I have to stop taking my current medications?
The trial may require you to stop taking certain medications, especially if they could interact with ketamine or increase the risk of participation. The protocol mentions a treatment-free period, which suggests you might need to stop some medications temporarily.
How does the drug ketamine differ from other treatments for obsessive-compulsive disorder?
What evidence supports the effectiveness of ketamine for treating obsessive-compulsive disorder?
Who Is on the Research Team?
Carolyn Rodriguez, MD, PhD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with a primary diagnosis of OCD who can give informed consent. Participants should have severe enough OCD symptoms to warrant the study and be able to go without other treatments for a while.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single infusion of either ketamine or midazolam
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine
- Midazolam
Ketamine is already approved in United States, European Union, Canada for the following indications:
- Anesthesia
- Treatment-resistant depression
- Anesthesia
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
University of Connecticut
Collaborator